RPS2P2: A Potential Drug Target and Biomarker for Diseases (G326325)

Target Name: RPS2P2

NCBI ID: G326325

RPS2P2

Other Name(s): RPS2_17_1389 | ribosomal protein S2 pseudogene 2 | Ribosomal protein S2 pseudogene 2

RPS2P2: A Potential Drug Target and Biomarker for Diseases

RPS2P2 (RPS2P2) is a protein that is expressed in the endoplasmic reticulum (ER) and is involved in the regulation of protein translation. It is a key player in the regulation of protein synthesis, which is a critical process for the development and maintenance of cellular organisms. RPS2P2 is a potential drug target and has been identified as a biomarker for various diseases, including cancer.

The RPS2P2 protein is composed of 219 amino acid residues and has a calculated molecular weight of 34 kDa. It is located in the ER and is involved in the regulation of protein translation. This protein is expressed in most tissues and cells of the body and is primarily localized to the endoplasmic reticulum.

RPS2P2 is involved in the regulation of protein translation by interacting with several cellular structures, including the cytoplasmic alpha-globin subunit of ribosomes. This interaction between RPS2P2 and alpha-globin allows for the regulation of protein translation and is a critical step in the regulation of protein synthesis.

In addition to its role in protein translation regulation, RPS2P2 is also involved in the regulation of protein degradation. This protein is known to interact with the protein degradation machinery and is involved in the regulation of protein degradation in the ER.

RPS2P2 is a potential drug target because of its involvement in the regulation of protein synthesis and degradation. This protein is a target for small molecules and other therapeutic compounds that can modulate its activity.

In addition to its potential as a drug target, RPS2P2 is also a potential biomarker for various diseases. This protein is expressed in most tissues and cells of the body and is primarily localized to the endoplasmic reticulum. Therefore, changes in the level of RPS2P2 expression can be an indication of the presence of certain diseases.

For example, RPS2P2 is downregulated in many types of cancer, including breast, ovarian, and prostate cancers. This suggests that RPS2P2 may be a useful biomarker for the diagnosis and treatment of these cancers. Additionally, RPS2P2 is also downregulated in diseases such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. This suggests that these diseases may also be good targets for the development of new therapeutic compounds.

In conclusion, RPS2P2 is a protein that is involved in the regulation of protein synthesis and degradation. It is a potential drug target and has been identified as a biomarker for various diseases, including cancer. Further research is needed to fully understand the role of RPS2P2 in cellular biology and its potential as a therapeutic compound.

Protein Name: Ribosomal Protein S2 Pseudogene 2

The "RPS2P2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPS2P2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets